Analyst Activity – HC Wainwright Initiates Coverage On Azurrx Biopharm (NASDAQ:AZRX) With a Buy

Analyst Ratings For Azurrx Biopharm (NASDAQ:AZRX)

Story continues below

Today, HC Wainwright initiated coverage on Azurrx Biopharm (NASDAQ:AZRX) with a Buy with a price target of $8.00.

There are 2 buy ratings on the stock.

The current consensus rating on Azurrx Biopharm (NASDAQ:AZRX) is Buy (Score: 3.00) with a consensus target price of $7.50 per share, a potential 82.48% upside.

Some recent analyst ratings include

  • 7/24/2017-HC Wainwright initiated coverage with a Buy rating.
  • 12/6/2016-WallachBeth Capital initiated coverage with a Buy rating.


  • On 6/30/2017 Pelican Partners Llc, Major Shareholder, sold 160,000 with an average share price of $3.19 per share and the total transaction amounting to $510,400.00. View SEC Filing

Recent Trading Activity for Azurrx Biopharm (NASDAQ:AZRX)
Shares of Azurrx Biopharm closed the previous trading session at with 103,955 shares trading hands.

An ad to help with our costs